- Home
- PSNL vs PGEN Comparison
PSNL vs PGEN Comparison
Compare PSNL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- PGEN
- Stock Information
- Founded
- PSNL 2011
- PGEN 1998
- Country
- PSNL United States
- PGEN United States
- Employees
- PSNL N/A
- PGEN N/A
- Industry
- PSNL Medical Specialities
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- PGEN Health Care
- Exchange
- PSNL Nasdaq
- PGEN Nasdaq
- Market Cap
- PSNL 321.1M
- PGEN 292.6M
- IPO Year
- PSNL 2019
- PGEN N/A
- Fundamental
- Price
- PSNL $3.89
- PGEN $0.82
- Analyst Decision
- PSNL Strong Buy
- PGEN Buy
- Analyst Count
- PSNL 4
- PGEN 5
- Target Price
- PSNL $6.81
- PGEN $7.00
- AVG Volume (30 Days)
- PSNL 845.3K
- PGEN 792.5K
- Earning Date
- PSNL 11-06-2024
- PGEN 11-26-2024
- Dividend Yield
- PSNL N/A
- PGEN N/A
- EPS Growth
- PSNL N/A
- PGEN N/A
- EPS
- PSNL N/A
- PGEN N/A
- Revenue
- PSNL $87,489,000.00
- PGEN $3,963,000.00
- Revenue This Year
- PSNL $14.85
- PGEN N/A
- Revenue Next Year
- PSNL $4.19
- PGEN $211.35
- P/E Ratio
- PSNL N/A
- PGEN N/A
- Revenue Growth
- PSNL 24.05
- PGEN N/A
- 52 Week Low
- PSNL $1.02
- PGEN $0.78
- 52 Week High
- PSNL $7.20
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- PSNL 37.60
- PGEN 40.32
- Support Level
- PSNL $4.15
- PGEN $0.89
- Resistance Level
- PSNL $5.40
- PGEN $1.05
- Average True Range (ATR)
- PSNL 0.50
- PGEN 0.06
- MACD
- PSNL -0.10
- PGEN 0.00
- Stochastic Oscillator
- PSNL 3.02
- PGEN 14.50
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.